{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:34:38Z","timestamp":1772120078547,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.bbrc.2020.03.139","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T02:31:00Z","timestamp":1585794660000},"page":"612-617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2\/BCL-XL inhibitor is overcome by BIM upregulation in ovarian clear cell carcinoma cells"],"prefix":"10.1016","volume":"526","author":[{"given":"Akane","family":"Inoue-Yamauchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2020.03.139_bib1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ygyno.2011.01.005","article-title":"Clear cell carcinoma of the ovary: a report from the first ovarian clear cell symposium, June 24th, 2010","volume":"121","author":"Anglesio","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbrc.2020.03.139_bib2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2012.04.021","article-title":"Clear cell carcinoma of the ovary: a review of the literature","volume":"126","author":"del Carmen","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbrc.2020.03.139_bib3","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","article-title":"Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy","volume":"88","author":"Sugiyama","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2020.03.139_bib4","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/jcp.2006.040030","article-title":"Ovarian clear cell adenocarcinoma: a continuing enigma","volume":"60","author":"Tan","year":"2007","journal-title":"J.\u00a0Clin. Pathol."},{"key":"10.1016\/j.bbrc.2020.03.139_bib5","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/IGC.0b013e3181dd0110","article-title":"Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer","volume":"20","author":"Mackay","year":"2010","journal-title":"Int. J. Gynecol. Canc."},{"key":"10.1016\/j.bbrc.2020.03.139_bib6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1182\/blood.V80.4.879.879","article-title":"Bcl-2 initiates a new category of oncogenes: regulators of cell death","volume":"80","author":"Korsmeyer","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2020.03.139_bib7","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.03.139_bib8","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Canc. Res."},{"key":"10.1016\/j.bbrc.2020.03.139_bib9","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2011.37.0981","article-title":"Targeting the B-cell lymphoma\/leukemia 2 family in cancer","volume":"30","author":"Davids","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.bbrc.2020.03.139_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cophys.2018.03.005","article-title":"BH3-dependent and independent activation of BAX and BAK in mitochondrial apoptosis","volume":"3","author":"Jeng","year":"2018","journal-title":"Curr. Opin. Physiol."},{"key":"10.1016\/j.bbrc.2020.03.139_bib11","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","article-title":"Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors","volume":"29","author":"Gandhi","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.bbrc.2020.03.139_bib12","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1200\/JCO.2011.37.9339","article-title":"From mitochondrial biology to magic bullet: navitoclax disarms BCL-2 in chronic lymphocytic leukemia","volume":"30","author":"Walensky","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.bbrc.2020.03.139_bib13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.seminhematol.2014.05.008","article-title":"Targeting BCL2 for the treatment of lymphoid malignancies","volume":"51","author":"Anderson","year":"2014","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bbrc.2020.03.139_bib14","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2020.03.139_bib15","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1164\/rccm.201009-1440OC","article-title":"Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor","volume":"183","author":"Chang","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.bbrc.2020.03.139_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147344","article-title":"ZEB1 mediates acquired resistance to the epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer","volume":"11","author":"Yoshida","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.bbrc.2020.03.139_bib17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1158\/1078-0432.CCR-17-1577","article-title":"Epithelial-to-Mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM","volume":"24","author":"Song","year":"2018","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.bbrc.2020.03.139_bib18","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41388-018-0482-y","article-title":"Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer","volume":"38","author":"Yochum","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2020.03.139_bib19","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1172\/JCI77075","article-title":"Taspase1-dependent TFIIA cleavage coordinates head morphogenesis by limiting Cdkn2a locus transcription","volume":"125","author":"Takeda","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.bbrc.2020.03.139_bib20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1158\/1535-7163.MCT-09-0651","article-title":"Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia\/lymphoma cell lines","volume":"9","author":"Tahir","year":"2010","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.bbrc.2020.03.139_bib21","doi-asserted-by":"crossref","first-page":"E1288","DOI":"10.1073\/pnas.1411848112","article-title":"Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer","volume":"112","author":"Faber","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bbrc.2020.03.139_bib22","doi-asserted-by":"crossref","first-page":"16078","DOI":"10.1038\/ncomms16078","article-title":"Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy","volume":"8","author":"Inoue-Yamauchi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2020.03.139_bib23","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2020.03.139_bib24","doi-asserted-by":"crossref","first-page":"831","DOI":"10.15252\/emmm.201404396","article-title":"ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat","volume":"7","author":"Meidhof","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bbrc.2020.03.139_bib25","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1158\/0008-5472.CAN-18-2052","article-title":"Epithelial-to-Mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status","volume":"79","author":"Fukuda","year":"2019","journal-title":"Canc. Res."},{"key":"10.1016\/j.bbrc.2020.03.139_bib26","first-page":"4916","article-title":"FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases","volume":"62","author":"Furumai","year":"2002","journal-title":"Canc. Res."},{"key":"10.1016\/j.bbrc.2020.03.139_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-2407-12-91","article-title":"EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer","volume":"12","author":"Haslehurst","year":"2012","journal-title":"BMC Canc."},{"key":"10.1016\/j.bbrc.2020.03.139_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151089","article-title":"Cisplatin resistant spheroids model clinically relevant survival mechanisms in ovarian tumors","volume":"11","author":"Chowanadisai","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.bbrc.2020.03.139_bib29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/onc.2015.84","article-title":"miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin","volume":"35","author":"Zhu","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2020.03.139_bib30","doi-asserted-by":"crossref","first-page":"99482","DOI":"10.18632\/oncotarget.20107","article-title":"Inhibition of ZEB1 leads to inversion of metastatic characteristics and restoration of paclitaxel sensitivity of chronic chemoresistant ovarian carcinoma cells","volume":"8","author":"Sakata","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2020.03.139_bib31","doi-asserted-by":"crossref","first-page":"22384","DOI":"10.1074\/jbc.M111.239566","article-title":"Bim protein degradation contributes to cisplatin resistance","volume":"286","author":"Wang","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2020.03.139_bib32","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1593\/neo.121784","article-title":"Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2\/SIN3a deacetylating complex","volume":"15","author":"Piazza","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbrc.2020.03.139_bib33","doi-asserted-by":"crossref","first-page":"16090","DOI":"10.1073\/pnas.0505585102","article-title":"Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim","volume":"102","author":"Zhao","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2020.03.139_bib34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1593\/neo.81358","article-title":"Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment","volume":"11","author":"Yang","year":"2009","journal-title":"Neoplasia"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20306367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20306367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:50:03Z","timestamp":1757764203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X20306367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0006291X20306367"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.03.139","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2\/BCL-XL inhibitor is overcome by BIM upregulation in ovarian clear cell carcinoma cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.03.139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}